Drug Research
FDA Approves Roche’s Susvimo for Diabetic Macular Edema
Roche has announced that the U.S. Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL as the first and only continuous...
Clinical Trials
EYLEA HD® Phase 3 Trial Yields Promising Results
Regeneron Pharmaceuticals, Inc. announced promising results from the Phase 3 QUASAR trial investigating EYLEA HD® (aflibercept) Injection 8 mg for treating macular edema in...
Clinical Trials
Pfizer’s BRAFTOVI Improves Survival in Phase 3 Trial
Pfizer has announced groundbreaking results from the Phase 3 BREAKWATER trial, showcasing the effectiveness of its BRAFTOVI® (encorafenib) combination regimen in the treatment of...
Press Releases
FlyPharma 2025 Amsterdam officially announced as contracts are signed with host sponsors
FlyPharma, the leading platform for the pharmaceutical logistics and supply chain industry, is thrilled to announce its ninth European conference, which will take place...
Press Releases
Neopac Becomes First European Tube Manufacturer to Achieve RecyClass EN 15343 Certification
Oberdiessbach, Switzerland – Neopac, a global provider of high-quality packaging and dosing applications for pharma, beauty and oral care, has successfully passed the RecyClass...
Press Releases
ACD/Labs Releases State-of-the-Industry Report Highlighting Trends in Chemical Structure Elucidation & Verification
Toronto, CANADA—ACD/Labs, an informatics company that develops and commercializes software in support of digitalized R&D, today released its 2025 Structure Elucidation & Verification Report....
Press Releases
Synexa Life Sciences Achieves Highest Level My Green Lab Certification, Reinforcing Commitment to Lab Sustainability
– Life Science Newswire – Synexa Life Sciences, a global provider of biomarker and bioanalytical solutions to the pharmaceutical, biotech, and CRO industries,...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read
